![]() |
|
|
Vol. 54, Issue 2, 379-388, August 1998
CNS Diseases Research, Pharmacia & Upjohn, Inc., Kalamazoo,
Michigan 49001
To investigate the roles of individual transmembrane segments (TM) of
the human D3 dopamine receptor in its
ligand-receptor interactions, we generated chimeric receptors in which
its TMs were replaced, one at a time, partially or entirely, by the
corresponding TM of the homologous human D1 receptor.
Ligand binding properties of the chimeras, as expressed heterologously
in Sf9 cells using recombinant baculoviruses, indicate that the
critical binding regions for D3-selective (over
D1) ligands reside at narrow regions (6 to 8 residues) near
the extracellular surface for TMI, II, IV and VI, while TMV seems to be
minimally involved in the ligand selectivity. For TMIII and TMVII, the
critical regions seem to be deeper, involving at least the 10 residues
near the extracellular surface for TMIII, and the entire TM segment for
TMVII. This is based on our current observations that the chimeras with
the D3 sequence in the critical regions, although the rest
of the TM is of D1 origin (except TMVII), showed the
binding properties indistinguishable from those of the wild-type
receptor. The chimeras with the D1 sequence in the
regions, on the other hand, showed ligand binding characteristics
wildly variable depending on substituted TMs: Most marked decreases in
ligand affinities were observed with the chimeras of TMIII and VII, and
intermediate changes with those of TMIV and VI. Replacements of TMV
produced no appreciable effects on the affinities of 14 test ligands
(except for one). The chimeras of TMI and II with the D1
sequence in the critical regions showed no appreciable specific binding
for several radioactive D3-selective ligands, possibly
reflecting their critical roles in assembly and folding of the
receptor. These critical regions of the D3 receptor were
highly homologous to those of the D2 receptor, except for
several nonconservatively substituted residues, which could be
exploited to develop ligands selective for the D3 over D2 dopamine receptor or vice versa.
This article has been cited by other articles:
![]() |
L. H. Heitman, J. Oosterom, K. M. Bonger, C. M. Timmers, P. H. G. Wiegerinck, and A. P. IJzerman [3H]Org 43553, the First Low-Molecular-Weight Agonistic and Allosteric Radioligand for the Human Luteinizing Hormone Receptor Mol. Pharmacol., February 1, 2008; 73(2): 518 - 524. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Yin, S. Gavi, H.-y. Wang, and C. C. Malbon Probing Receptor Structure/Function with Chimeric G-Protein-Coupled Receptors Mol. Pharmacol., June 1, 2004; 65(6): 1323 - 1332. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Iwasiow, M.-F. Nantel, and M. Tiberi Delineation of the Structural Basis for the Activation Properties of the Dopamine D1 Receptor Subtypes J. Biol. Chem., November 5, 1999; 274(45): 31882 - 31890. [Abstract] [Full Text] [PDF] |
||||